Beneficial effects of SR33805 in failing myocardium

Cardiovascular Research

Volumn 91, Issue 3, 2011, Pages 412-419

  Ait Mou, Younss ^a,b   Toth, Attila ^c   Cassan, Cécile ^a   Czuriga, Daniel ^c   De Tombe, Pieter P ^b   Papp, Zoltan ^c   Lacampagne, Alain ^a   Cazorla, Olivier ^a  

^a UNIVERSITY OF MONTPELLIER   (France)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Contractile function; Heart failure; Myocytes; Sarcomere; Ventricular function

Indexed keywords

2 [4 [3 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]PROPOXY]BENZENESULFONYL] 3 ISOPROPYL 1 METHYLINDOLE; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; MYOSIN LIGHT CHAIN 2; TRITON X 100; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; MALE; MUSCLE CELL; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; RAT; SENSITIVITY ANALYSIS; SENSITIZATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; CARDIAC MYOSINS; CARDIOTONIC AGENTS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; EXCITATION CONTRACTION COUPLING; HEART FAILURE; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; MYOFIBRILS; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; SULFONES; TIME FACTORS; TROPONIN I;

EID: 79960819821     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr096     Document Type: Article

References (42)

1. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 2006;7:2179-2202.
2. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther 2001;15:397-403.
3. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem 2004;266:87-107. (Pubitemid 39562310)
4. 2+ -sensitizing properties in cardiac myocytes. Br J Pharmacol 2003;139:99-108. (Pubitemid 36645313)
5. 2+ channel in rat heart sarcolemmal membrane. Eur J Pharmacol 1994;267:151-160. (Pubitemid 24123021)
6. 2+ entry blocker: SR 33805. Eur J Pharmacol 1993;246:181-193. (Pubitemid 23253674)
7. Ieiri S, Hirano K, Nishimura J, Suita S, Kanaide H. Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery. Br J Pharmacol 2000;131:1597-1606. (Pubitemid 32056425)
8. Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu Rev Physiol 2005;67:39-67. (Pubitemid 40404485)
9. Ait Mou Y, Reboul C, Andre L, Lacampagne A, Cazorla O. Late exercise training improves non-uniformity of transmural myocardial function in rats with ischaemic heart failure. Cardiovasc Res 2009;81:555-564.
10. Cazorla O, Szilagyi S, Le Guennec JY, Vassort G, Lacampagne A. Transmural stretchdependent regulation of contractile properties in rat heart and its alteration after myocardial infarction. FASEB J 2005;19:88-90. (Pubitemid 40069927)
11. Kobayashi T, Jin L, de Tombe PP. Cardiac thin filament regulation. Pflugers Arch 2008; 457:37-46.
12. Edes IF, Toth A, Csanyi G, Lomnicka M, Chlopicki S, Edes I et al. Late-stage alterations in myofibrillar contractile function in a transgenic mouse model of dilated cardiomyopathy (Tgalphaq *44). J Mol Cell Cardiol 2008;45:363-372.
13. Zhang H., Chen X, Gao E, MacDonnell SM, Wang W, Kolpakov M et al. Increasing cardiac contractility after myocardial infarction exacerbates cardiac injury and pump dysfunction. Circ Res 2010;107:800-809.
14. 2+ sensitizers. Circ J 2008;72:1915-1925.
15. Shioura KM, Farjah M, Geenen DL, Solaro RJ, Goldspink PH. Myofilament calcium sensitization delays decompensated hypertrophy differently between the sexes following myocardial infarction. Am J Physiol Regul Integr Comp Physiol 2011;300: R361-R368.
16. Romey G, Lazdunski M. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther 1994;271:1348-1352. (Pubitemid 24382644)
17. Bokenes J, Aronsen JM, Birkeland JA, Henriksen UL, Louch WE, Sjaastad I et al. Slow contractions characterize failing rat hearts. Basic Res Cardiol 2008;103:328-344.
18. 2+]i in rat ventricular myocytes following myocardial infarction. J Physiol 1999;517(Pt 1):229-245. (Pubitemid 29243484)
19. Lee JA, Allen DG. EMD 53998 sensitizes the contractile proteins to calcium in intact ferret ventricular muscle. Circ Res 1991;69:927-936.
20. 2+ in isolated ferret cardiac muscle. Circ Res 1993;73:61-70. (Pubitemid 23173056)
21. Hajjar RJ, Schmidt U, Helm P, Gwathmey JK. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 1997;280:247-254. (Pubitemid 27171409)
22. Solaro RJ, Gambassi G,Warshaw DM, Keller MR, Spurgeon HA, Beier N et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993;73:981-990. (Pubitemid 23340194)
23. Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001;10:955-970. (Pubitemid 32421987)
24. Masutani S, Cheng HJ, Hyttila-Hopponen M, Levijoki J, Heikkila A, Vuorela A et al. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs. J Pharmacol Exp Ther 2008;325:236-247. (Pubitemid 351439153)
25. Chan JY, Takeda M, Briggs LE, Graham ML, Lu JT, Horikoshi N et al. Identification of cardiac-specific myosin light chain kinase. Circ Res 2008;102:571-580. (Pubitemid 351416756)
26. Richard S, Perrier E, Fauconnier J, Perrier R, Pereira L, Gomez AM et al. 'Ca(2+)- induced Ca(2+) entry' or how the L-type Ca(2+) channel remodels its own signaling pathway in cardiac cells. Prog Biophys Mol Biol 2006;90:118-135. (Pubitemid 41721047)
27. Arteaga GM, Palmiter KA, Leiden JM, Solaro RJ. Attenuation of length dependence of calcium activation in myofilaments of transgenic mouse hearts expressing slow skeletal troponin I. J Physiol 2000;526(Pt 3):541-549. (Pubitemid 30649617)
28. 2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol 2003;552:845-857. (Pubitemid 37428425)
29. Morano I. Tuning the human heart molecular motors by myosin light chains. J Mol Med 1999;77:544-555. (Pubitemid 29426312)
30. Chandra M, Dong WJ, Pan BS, Cheung HC, Solaro RJ. Effects of protein kinase A phosphorylation on signaling between cardiac troponin I and the N-terminal domain of cardiac troponin C. Biochemistry 1997;36:13305-13311. (Pubitemid 27473378)
31. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009;81:519-527.
32. Bers DM. Calcium and cardiac rhythms: physiological and pathophysiological. Circ Res 2002;90:14-17. (Pubitemid 34074602)
33. Kruger M, Linke WA. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil 2006;27: 435-444. (Pubitemid 44325622)
34. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest 1996;98: 167-176. (Pubitemid 26243833)
35. Hamdani N, Kooij V, van Dijk S, Merkus D, Paulus WJ, Remedios CD et al. Sarcomeric dysfunction in heart failure. Cardiovasc Res 2008;77:649-658. (Pubitemid 351301859)
36. 2+ transients in human ventricular and atrial myocardium. Z Kardiol 2002;91:312-318. (Pubitemid 34438035)
37. Kristof E, Szigeti G, Papp Z, Bodi A, Ball NA, Walsh RA et al. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 1999;94:223-230. (Pubitemid 29419489)
38. Ke Y, Wang L, Pyle WG, de Tombe PP, Solaro RJ. Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circ Res 2004;94: 194-200. (Pubitemid 38197451)
39. Ke Y, Butt AG, Swart M, Liu YF, McDonald FJ. COMMD1 downregulates the epithelial sodium channel through Nedd4-2. Am J Physiol Renal Physiol 2010;298: F1445-F1456.
40. Kaumann A, Bartel S, Molenaar P, Sanders L, Burrell K, Vetter D et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999;99:65-72. (Pubitemid 29035959)
41. 2+- sensitivity in heart failure: increased or decreased?. J Mol Cell Cardiol 2008;45: 603-607.
42. Hamdani N, Paulus WJ, van Heerebeek L, Borbely A, Boontje NM, Zuidwijk MJ et al. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur Heart J 2009;30:1863-1872.